For the quarter ending 2025-09-30, AGEN has $233,891K in assets. $3,458K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,458 | 9,534 | ||
| Accounts receivable | 538 | 709 | ||
| Related party note receivable from mink therapeutics, inc-Related Party | 5,725 | - | ||
| Prepaid expenses | 885 | 1,337 | ||
| Assets held for sale | 122,149 | - | ||
| Other current assets | 1,195 | 1,760 | ||
| Total current assets | 133,950 | 13,340 | ||
| Property, plant and equipment, net of accumulated amortization and depreciation of 47,166 and 72,553 at september 30, 2025 and december 31, 2024, respectively | 15,987 | 112,722 | ||
| Operating lease right-of-use assets | 8,027 | 26,421 | ||
| Goodwill | 24,092 | 24,092 | ||
| Acquired intangible assets, net of accumulated amortization of 17,240 and 16,986 at september 30, 2025 and december 31, 2024, respectively | 3,122 | 3,206 | ||
| Equity method investment in mink therapeutics, inc | 30,482 | - | ||
| Due from related parties (mink therapeutics, inc.)-Related Party | 15,043 | - | ||
| Other long-term assets | 3,188 | 5,440 | ||
| Total assets | 233,891 | 185,221 | ||
| Current portion, long-term debt | 10,610 | 10,721 | ||
| Current portion, liability related to sale of future royalties and milestones | 103,047 | 103,703 | ||
| Current portion, deferred revenue | 45 | 45 | ||
| Current portion, operating lease liabilities | 1,113 | 2,496 | ||
| Accounts payable | 85,289 | 74,396 | ||
| Accrued liabilities | 31,752 | 39,311 | ||
| Liabilities held for sale | 54,566 | - | ||
| Other current liabilities | 710 | 3,891 | ||
| Total current liabilities | 287,132 | 234,563 | ||
| Long-term debt, net of current portion | 23,599 | 23,151 | ||
| Liability related to sale of future royalties and milestones, net of current portion | 192,126 | 208,526 | ||
| Deferred revenue, net of current portion | 1,143 | 1,143 | ||
| Operating lease liabilities, net of current portion | 10,383 | 53,394 | ||
| Other long-term liabilities | 376 | 752 | ||
| Series a-1 convertible preferred stock 31,620 shares designated, issued, and outstanding at september 30, 2025 and december 31, 2024 liquidation value of 34,263 at september 30, 2025-Series A1Convertible Preferred Stock | 0 | 0 | ||
| Common stock, par value 0.01 per share 800,000,000 shares authorized 32,814,429 and 23,634,670 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 329 | 300 | ||
| Additional paid-in capital | 1,899,281 | 1,882,704 | ||
| Accumulated other comprehensive loss | -1,560 | -1,504 | ||
| Accumulated deficit | -2,172,187 | -2,236,101 | ||
| Total stockholders' deficit attributable to agenus inc | -274,137 | -354,601 | ||
| Non-controlling interest | -6,731 | 18,293 | ||
| Total stockholders' deficit | -280,868 | -336,308 | ||
| Total liabilities and stockholders' deficit | 233,891 | 185,221 | ||
AGENUS INC (AGEN)
AGENUS INC (AGEN)